Although various types of treatment of @entity157 ( @entity157 ) have been tried, the prognosis remains dismal, especially in @entity1 with advanced stage of the disease. @entity1943 analogues exert antitumor effects. @entity157 have been shown to exhibit @entity1943 receptors. The present randomized placebo-controlled study aimed at examining the efficacy of long-acting octreotide ( @entity2390 LAR) for the treatment of advanced @entity157 . Seventy @entity1 were randomized to receive a 2-week course of 250 microg short-acting octreotide twice daily followed by @entity2390 LAR 30 mg injection once every 4 weeks for 6 doses (n = 35) or placebo (control group) (n = 35). The clinical and laboratory parameters were monitored. There was no difference in the cumulative survival between the @entity2390 LAR-treated group compared with the control group [median survival 1.93 months vs. 1.97 months, respectively, P = NS (log-rank test)]. There was no @entity5 regression and no reduction of @entity160 ( @entity160 ) levels in @entity1 receiving @entity2390 LAR treatment. There was no improvement of quality of life assessed by Karnofsky performance score. In conclusion, @entity2390 LAR monotherapy did not have survival benefit in our selected group of @entity1 with advanced @entity157 . Further studies should be performed in @entity1 with @entity1442 and/or different etiology to evaluate its benefit.

A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity1943 :: ('MESH:D013004', 'Chemical') :: ['somatostatin', 'Somatostatin'] @entity160 :: ('174', 'Gene') :: ['alpha-fetoprotein', 'AFP'] @entity1442 :: ('MESH:D020178', 'Disease') :: ['less advanced disease'] @entity2390 :: ('MESH:D015282', 'Chemical') :: ['Sandostatin'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma']
@entity157 :: (MESH:D006528,Disease) :: ['hepatocellular carcinoma']
